The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for SAR’579 / IPH6101 – an innovative treatment for hematological malignancies developed jointly by Innate Pharma SA and Sanofi – allowing it to be brought to patients sooner. This groundbreaking process is designed to offer potential solutions for serious conditions and assist with filling unmet medical needs. Thanks to the FDA, SAR’579 / IPH6101 is now one step closer to being available to countless patients.
SAR’579, the lead asset of the ANKET® platform, is a revolutionary trifunctional anti-CD123 NKp46xCD16 NK cell engager developed through a strategic partnership between Innate Pharma and Sanofi. Being studied by Sanofi for its potential to radically change the game, this remarkable achievement has the potential to transform the world of immuno-oncology.
We are delighted to announce that SAR’579 / IPH6101 has been granted Fast Track Designation in the US by the FDA for the treatment of hematological malignancies! Our partner Sanofi has achieved a significant milestone with this designation, which further highlights the potential of our ANKET® platform to treat cancer patients with NK Cell Engagers. These positive developments come off the back of the encouraging clinical data presented at the 2023 ASCO Annual Meeting.
About ANKET®
ANKET® (Antibody-based NK cell Engager Therapeutics) is Innate’s proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer.
This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer.
About the Innate-Sanofi agreements:
Innate and Sanofi have come together to bring their combined cutting-edge technologies to the table and develop groundbreaking multi-specific antibodies that engage Natural Killer cells to destroy cancer cells, giving us even more hope in our fight against this disease. Both NKp46 and CD16 activating receptors will be used to bring about this exciting new cancer-busting development.
Innate Pharma and Sanofi have formed an exciting new research collaboration and license agreement. This agreement will see Sanofi take charge of developing, manufacturing and commercializing products stemming from the research collaboration, which includes IPH6101/SAR’579 and IPH6401/SAR’514. In return, Innate Pharma is eligible to receive up to €400m in milestone payments and royalties on net sales earned. It’s an agreement that truly emphasizes the power of partnership!
About Innate Pharma
Innate Pharma S.A. is a revolutionary biotechnology company paving the way to a new era of cancer management. Through its proprietary ANKET® (Antibody-based NK cell Engager Therapies) platform, Innate Pharma is capitalizing on the body’s own natural defense mechanisms to develop potentially groundbreaking immunotherapies for cancer patients. With a multidisciplinary team of clinical professionals, Innate Pharma is dedicated to delivering life-saving treatments and a brighter future for those fighting against cancer.
Innate Pharma, a research and development partner for biopharmaceutical companies, research institutions, and patients, is a leader in cutting-edge therapies for advanced cases of cutaneous T-cell lymphomas and peripheral T-cell lymphomas with their lead proprietary program Lacutamab, and in non-small cell lung cancer with their Monalizumab developed in collaboration with AstraZeneca.
Furthermore, Innate Pharma continues to innovate with their ANKET® multi-specific NK cell engagers that are designed to treat multiple forms of cancer. Located in Marseille, France, and Rockville, MD, USA, Innate Pharma continues to strive for excellence and can be traded on both Euronext Paris and the Nasdaq in the US.